Phase 3ACSCurrently Recruiting
Librexia ACS
Acute Coronary Syndrome
Protocol: Pfizer C4921003
About this study
Pivotal Phase 3 study evaluating a novel antithrombotic strategy in patients following an acute coronary syndrome event.
Sponsor: Pfizer
Key eligibility
- Adults with recent ACS event
- Clinically stable for randomization
- On standard-of-care therapy
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.
What participation involves
Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.
Note
This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.